Update on Availability of Cimerli, a Biosimilar to Lucentis
Cimerli is supplied as a single-dose glass vial designed to deliver 0.05mL of 10mg/mL or 6mg/mL ranibizumab-eqrn solution for intravitreal injection.
Diagnosis & Disease Information
Tarcocimab Improves Vision in Patients With Macular Edema Due to Retinal Vein Occlusion
Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.
Cimerli Approved as Interchangeable Biosimilar to Lucentis
The approval of Cimerli was based on a comprehensive analytical, preclinical and clinical program including the phase 3 COLUMBUS-AMD study.
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Lutein/Zeaxanthin in AREDS2 May Slow Progression to Late AMD
No increased risk for lung cancer, reduced risk for progression to late AMD seen with lutein/zeaxanthin as replacement for beta-carotene
Update on Availability of Byooviz, a Biosimilar to Lucentis
Byooviz (ranibizumab-nuna) is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Continued Monitoring Needed for Anti-VEGF Therapy in Macular Edema
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Xipere Now Available for Macular Edema Associated With Uveitis
Xipere approval was based on data from the phase 3 PEACHTREE trial, which included 160 patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis.
New Drug Product: Vabysmo
This slideshow show drug information for Vabysmo. Click here for the complete Vabysmo monograph.
Trials Show Promise for Intravitreal Faricimab in Retinal Disease
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
